Stock fact sheet · data as of
Organigram Global Inc. (OGI): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - Specialty & Generic · Canada · High Growth
Is OGI undervalued?
At 0.9316 (close of 16 Oct 2026), OGI trades 93% below the GLS average fair value of 13.02. That average comes from 5 models run on the latest filings, and 5 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Organigram Global Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
There is a wide gap between EPV (5.03) and Graham Growth (25.88). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files OGI under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for OGI
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 7.20 | +673% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 25.88 | +2678% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 11.31 | +1114% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 15.69 | +1585% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 5.03 | +440% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.5093 | -45% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Organigram Global Inc. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 1.9/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -5.0%, ROE -5.1%, ROA -3.2% - with debt at 0.03 times equity and negative free cash flow.
Organigram Global Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from International Business To Business 69%, Wholesale To Licensed Producers Revenue 25%, Direct To Patient Medical Revenue 6% (fiscal year FY2025).
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | -5.0% |
|---|---|---|---|
| GLS Moat | 1.9 / 10 | ROE | -5.1% |
| Debt / equity | 0.03 | ROA | -3.2% |
| Free-cash-flow yield | -15.6% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 55: Fair
A Wheel Score of 55 puts Organigram Global Inc. in the Fair band - below the 70 the Sunday Scan requires. Value 25/25, Health 11/20, Moat 3/15, Premium 10/20 and Stability 6/20; the weakest part is Moat (3/15).
Implied volatility is 101% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (10 of 20) because volatility this high usually comes with a reason. Chain open interest is 10,148 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 278k shares a day on a market cap of $131M, with a beta of 1.91 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 93% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 3 / 15 | moat 1.9/10 | |
| Premium | 10 / 20 | implied volatility 101% | |
| Stability | 6 / 20 | 278k shares/day, $131M cap, beta 1.91 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 15 Dec 2026, 60 days away - outside the window of a 30-45-day put sold today.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Organigram Global Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| CRDL Cardiol Therapeutics Inc. | 1.15 | 0.1478 | -678% | 21Weak | $139M |
| ORGO Organogenesis Holdings Inc. | 1.11 | 4.16 | +73% | 45Weak | $143M |
| DERM Journey Medical Corporation | 5.13 | - | - | 37Weak | $145M |
| CPIX Cumberland Pharmaceuticals Inc. | 7.54 | 22.07 | +66% | 45Weak | $113M |
| BGM BGM Group Ltd. | 8.59 | 6.82 | -26% | 7No options | $109M |
| AAWH Ascend Wellness Holdings, Inc. | 0.4050 | 4.17 | +90% | 39No options | $82M |
| SIGA SIGA Technologies, Inc. | 3.10 | 8.72 | +64% | 45Weak | $223M |
| ZYBT Zhengye Biotechnology Holding Limited | 1.53 | 10.85 | +86% | 36No options | $73M |
| LFCR Lifecore Biomedical, Inc. | 6.44 | - | - | 45Weak | $244M |
| ACB Aurora Cannabis Inc. | 4.10 | - | - | 45Weak | $260M |
| ELTP Elite Pharmaceuticals, Inc. | 0.2500 | 6.20 | +96% | 39No options | $269M |
| CGC Canopy Growth Corporation | 0.7355 | - | - | 37Weak | $311M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about OGI
Is OGI undervalued right now?
By the GLS models, yes: at 0.9316 the stock is 93% below the average fair value of 13.02 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of OGI and what does it mean?
OGI scores 55 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for OGI?
13.02 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Organigram Global Inc. report earnings next?
The next earnings report is due on 15 Dec 2026, 60 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does OGI have listed options, and how liquid are they?
Yes. The nightly snapshot found 44 listed contracts with 10,148 open interest across all expiries and implied volatility of 101% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.